Everipedia Logo
Everipedia is now IQ.wiki - Join the IQ Brainlist and our Discord for early access to editing on the new platform and to participate in the beta testing.


Antipsychotics, also known as neuroleptics or major tranquilizers,[2] are a class of medication primarily used to manage psychosis (including delusions, hallucinations, paranoia or disordered thought), principally in schizophrenia and bipolar disorder. Antipsychotics are usually effective in relieving symptoms of psychosis in the short term.

The long-term use of antipsychotics is associated with adverse effects such as involuntary movement disorders, gynecomastia, impotence, weight gain and metabolic syndrome.

First-generation antipsychotics, known as typical antipsychotics, were discovered in the 1950s. Most second-generation drugs, known as atypical antipsychotics, have been developed more recently, although the first atypical antipsychotic, clozapine, was discovered in the 1960s and introduced clinically in the 1970s.[3] Both generations of medication tend to block receptors in the brain's dopamine pathways, but atypicals tend to act on serotonin receptors as well. Neuroleptic, originating from Greek: νεῦρον (neuron) and λαμβάνω (take hold of) – thus meaning "which takes the nerve" – refers to both common neurological effects and side effects.[4]

Drug class
Class identifiers
UsePrincipally: Schizophrenia, bipolar disorder
Clinical data
Drugs.comDrug Classes [246]
External links
MeSHD014150 [247]
In Wikidata

Medical uses

Antipsychotics are most frequently used for the following conditions:

  • Schizophrenia

  • Schizoaffective disorder most commonly in conjunction with either an antidepressant (in the case of the depressive subtype) or a mood stabiliser (in the case of the bipolar subtype).

  • Bipolar disorder (acute mania and mixed episodes) may be treated with either typical or atypical antipsychotics, although atypical antipsychotics are usually preferred because they tend to have more favourable adverse effect profiles[5] and, according to a recent meta-analysis, they tend to have a lower liability for causing conversion from mania to depression.[6]

  • Psychotic depression. In this indication it is a common practice for the psychiatrist to prescribe a combination of an atypical antipsychotic and an antidepressant as this practice is best supported by the evidence.[7]

  • Treatment-resistant (and not necessarily psychotic) major depression as an adjunct to standard antidepressant therapy.[7]

They are not recommended for dementia or insomnia unless other treatments have not worked.[8] They are not recommended in children unless other treatments are not effective or unless the child has psychosis.[8]

The World Health Organization provides a description of recommendations for the prescription of antipsychotics for the purposes of the treatment of psychosis.[9]


Antipsychotic drug treatment is a key component of schizophrenia treatment algorithms recommended by the National Institute of Health and Care Excellence (NICE),[10] the American Psychiatric Association,[11] and the British Society for Psychopharmacology.[12] The main effect of treatment with antipsychotics is to reduce the so-called "positive" symptoms, including delusions and hallucinations. There is mixed evidence to support a significant impact of antipsychotic use on negative symptoms (such as apathy, lack of emotional affect, and lack of interest in social interactions) or on the cognitive symptoms (disordered thinking, reduced ability to plan and execute tasks) of schizophrenia.[13][14] In general, the efficacy of antipsychotic treatment in reducing both positive and negative symptoms appears to increase with increasing severity of baseline symptoms.[15] All antipsychotic medications work relatively the same way, by antagonizing D2 dopamine receptors. However, there are some differences when it comes to typical and atypical antipsychotics. For example, atypical antipsychotic medications have been seen to lower the neurocognitive impairment associated with schizophrenia more so than conventional antipsychotics, although the reasoning and mechanics of this are still unclear to researchers.[16]

Applications of antipsychotic drugs in the treatment of schizophrenia include prophylaxis in those showing symptoms that suggest that they are at high risk of developing psychosis, treatment of first episode psychosis, maintenance therapy, and treatment of recurrent episodes of acute psychosis.[12]

Prevention of psychosis and symptom improvement

Test batteries such as the PACE (Personal Assessment and Crisis Evaluation Clinic) and COPS (Criteria of Prodromal Syndromes), which measure low level psychotic symptoms, and others focused on cognitive disturbances (Basic symptoms"), are used to evaluate people with early, low level symptoms of psychosis. Used in combination with family history information, these tests can identify a "high risk" group having a 20–40% risk of progression to frank psychosis within 2 years.[12] These patients are often treated with low doses of antipsychotic drugs with the goal of reducing their symptoms and preventing progression to frank psychosis. While generally useful for reducing symptoms, the clinical trials performed to date provide little evidence that early use of antipsychotics, alone or in combination with cognitive-behavioral therapy, provides improved long term outcomes in those with prodromal symptoms.[17]

First episode psychosis

NICE recommends that all persons presenting with a first episode of frank psychosis be treated with both an antipsychotic drug and cognitive-behavioral therapy (CBT). NICE further recommends that those expressing a preference for CBT alone be informed that combination treatment is more efficacious.[10] A diagnosis of schizophrenia is not normally made at this time, as up to 25% of those presenting with first episode psychosis are eventually found to suffer from bipolar disorder instead. The goals of treatment of these patients include reducing symptoms and potentially improving long-term treatment outcomes. Randomized clinical trials have provided evidence for the efficacy of antipsychotic drugs in achieving the former goal, with first-generation and second generation antipsychotics showing about equal efficacy. Evidence that early treatment has a favorable effect on long term outcomes is equivocal.[10][12]

Recurrent psychotic episodes

Placebo-controlled trials of both first and second generation antipsychotic drugs consistently demonstrate the superiority of active drug to placebo in suppressing psychotic symptoms.[12] A large meta-analysis of 38 trials of antipsychotic drugs in schizophrenia acute psychotic episodes showed an effect size of about 0.5.[18] There is little or no difference in efficacy among approved antipsychotic drugs, including both first- and second-generation agents.[10][19] The efficacy of such drugs is suboptimal. Few patients achieve complete resolution of symptoms. Response rates, calculated using various cutoff values for symptom reduction, are low and their interpretation is complicated by high placebo response rates and selective publication of clinical trial results.[20]

Maintenance therapy

The majority of patients treated with an antipsychotic drug will experience a response within 4 weeks. The goals of continuing treatment are to maintain suppression of symptoms, prevent relapse, improve quality of life, and support engagement in psychosocial therapy.[12]

Maintenance therapy with antipsychotic drugs is clearly superior to placebo in preventing relapse, but is associated with weight gain, movement disorders, and high dropout rates.[21] A 3-year trial following persons receiving maintenance therapy after an acute psychotic episode found that 33% obtained long-lasting symptom reduction, 13% achieved remission, and only 27% experienced satisfactory quality of life. The effect of relapse prevention on long term outcomes is uncertain, as historical studies show little difference in long term outcomes before and after the introduction of antipsychotic drugs.[12]

A significant challenge in the use of antipsychotic drugs for the prevention of relapse is the poor rate of compliance. In spite of the relatively high rates of adverse effects associated with these drugs, some evidence, including higher dropout rates in placebo arms compared to treatment arms in randomized clinical trials, suggest that most patients who discontinue treatment do so because of suboptimal efficacy.[21][22]

Bipolar disorder

Antipsychotics are routinely used, often in conjunction with mood stabilisers such as lithium/valproate, as a first-line treatment for manic and mixed episodes associated with bipolar disorder.[7][23] The reason for this combination is the therapeutic delay of the aforementioned mood stabilisers (for valproate therapeutic effects are usually seen around five days after treatment is commenced whereas lithium usually takes at least a week[23] before the full therapeutic effects are seen) and the comparatively rapid antimanic effects of antipsychotic drugs.[24] The antipsychotics have a documented efficacy when used alone in acute mania/mixed episodes.[5]

Three atypical antipsychotics (lurasidone,[25] olanzapine[26] and quetiapine[27]) have also been found to possess efficacy in the treatment of bipolar depression as a monotherapy, whereas only olanzapine[28] and quetiapine[29][30] have been proven to be effective broad-spectrum (i.e. against all three types of relapse— manic, mixed and depressive) prophylactic (or maintenance) treatments in patients with bipolar disorder. A recent Cochrane review also found that olanzapine had a less favourable risk/benefit ratio than lithium as a maintenance treatment for bipolar disorder.[31]

The American Psychiatric Association and the UK National Institute for Health and Care Excellence recommend antipsychotics for managing acute psychotic episodes in schizophrenia or bipolar disorder, and as a longer-term maintenance treatment for reducing the likelihood of further episodes.[32][33] They state that response to any given antipsychotic can be variable so that trials may be necessary, and that lower doses are to be preferred where possible. A number of studies have looked at levels of "compliance" or "adherence" with antipsychotic regimes and found that discontinuation (stopping taking them) by patients is associated with higher rates of relapse, including hospitalization.


An assessment for an underlying cause of behavior is needed before prescribing antipsychotic medication for symptoms of dementia.[34] Antipsychotics in old age dementia showed a modest benefit compared to placebo in managing aggression or psychosis, but this is combined with a fairly large increase in serious adverse events. Thus, antipsychotics should not be used routinely to treat dementia with aggression or psychosis, but may be an option in a few cases where there is severe distress or risk of physical harm to others.[35] Psychosocial interventions may reduce the need for antipsychotics.[36]

Unipolar depression

A number of atypical antipsychotics have some benefits when used in addition to other treatments in major depressive disorder.[37][38] Aripiprazole, quetiapine, and olanzapine (when used in conjunction with fluoxetine) have received the Food and Drug Administration (FDA) labelling for this indication.[39] There is, however, a greater risk of side effects with their use.[37]


Besides the above uses antipsychotics may be used for obsessive–compulsive disorder, posttraumatic stress disorder, personality disorders, Tourette syndrome, autism and agitation in those with dementia.[40] Evidence however does not support the use of atypical antipsychotics in eating disorders or personality disorder.[41] Risperidone may be useful for obsessive–compulsive disorder.[40] The use of low doses of antipsychotics for insomnia, while common, is not recommended as there is little evidence of benefit and concerns regarding adverse effects.[41][42] Low dose antipsychotics may also be used in treatment of impulse-behavioural and cognitive-perceptual symptoms of borderline personality disorder.[43]

In children they may be used in those with disruptive behavior disorders, mood disorders and pervasive developmental disorders or intellectual disability.[44] Antipsychotics are only weakly recommended for Tourette syndrome, because although they are effective, side effects are common.[45] The situation is similar for those on the autism spectrum.[46] Much of the evidence for the off-label use of antipsychotics (for example, for dementia, OCD, PTSD, Personality Disorders, Tourette's) was of insufficient scientific quality to support such use, especially as there was strong evidence of increased risks of stroke, tremors, significant weight gain, sedation, and gastrointestinal problems.[47] A UK review of unlicensed usage in children and adolescents reported a similar mixture of findings and concerns.[48] A survey of children with pervasive developmental disorder found that 16.5% were taking an antipsychotic drug, most commonly for irritability, aggression, and agitation. Risperidone has been approved by the US FDA for the treatment of irritability in autistic children and adolescents.[49]

Aggressive challenging behavior in adults with intellectual disability is often treated with antipsychotic drugs despite lack of an evidence base. A recent randomized controlled trial, however, found no benefit over placebo and recommended that the use of antipsychotics in this way should no longer be regarded as an acceptable routine treatment.[50]

Antipsychotics may be an option, together with stimulants, in people with ADHD and aggressive behavior when other treatments have not worked.[51]

Typicals versus atypicals

It is unclear whether the atypical (second-generation) antipsychotics offer advantages over older, first generation antipsychotics.[14][52] Amisulpride, olanzapine, risperidone and clozapine may be more effective but are associated with greater side effects.[53] Typical antipsychotics have equal drop-out and symptom relapse rates to atypicals when used at low to moderate dosages.[54]

Clozapine is an effective treatment for those who respond poorly to other drugs ("treatment-resistant" or "refractory" schizophrenia),[55] but it has the potentially serious side effect of agranulocytosis (lowered white blood cell count) in less than 4% of people.[56]

Due to bias in the research the accuracy of comparisons of atypical antipsychotics is a concern.[57]

In 2005, a US government body, the National Institute of Mental Health published the results of a major independent study (the CATIE project).[58] No other atypical studied (risperidone, quetiapine, and ziprasidone) did better than the typical perphenazine on the measures used, nor did they produce fewer adverse effects than the typical antipsychotic perphenazine, although more patients discontinued perphenazine owing to extrapyramidal effects compared to the atypical agents (8% vs. 2% to 4%).[5]

Compliance has not been shown to be different between the two types.[59]

Many researchers question the first-line prescribing of atypicals over typicals, and some even question the distinction between the two classes.[60][61][62] In contrast, other researchers point to the significantly higher risk of tardive dyskinesia and other extrapyramidal symptoms with the typicals and for this reason alone recommend first-line treatment with the atypicals, notwithstanding a greater propensity for metabolic adverse effects in the latter.[63] The UK government organization NICE recently revised its recommendation favoring atypicals, to advise that the choice should be an individual one based on the particular profiles of the individual drug and on the patient's preferences.

The re-evaluation of the evidence has not necessarily slowed the bias toward prescribing the atypicals.[64]

Adverse effects

Biperiden is prescribed for acute extrapyramidal side effects of antypsychotic therapy, such as akathisia.[65]

Generally, more than one antipsychotic drug should not be used at a time because of increased adverse effects.[66]

Very rarely antipsychotics may cause tardive psychosis.[67]

By rate

Common (≥ 1% and up to 50% incidence for most antipsychotic drugs) adverse effects of antipsychotics include[68]
  • Sedation (particularly common with asenapine, clozapine, olanzapine, quetiapine, chlorpromazine and zotepine[19])

  • Headaches

  • Dizziness

  • Diarrhea

  • Anxiety

  • Extrapyramidal side effects (particularly common with first-generation antipsychotics), which include:

Akathisia— an often distressing sense of inner restlessness.
  • Tremor
  • Hyperprolactinaemia (rare for those treated with clozapine, quetiapine and aripiprazole[7][19]), which can cause:

Galactorrhoea— unusual secretion of breast milk.
  • Sexual dysfunction (in both sexes)
  • Osteoporosis
  • Orthostatic hypotension

  • Weight gain (particularly prominent with clozapine, olanzapine, quetiapine and zotepine[19])

  • Anticholinergic side-effects (common for olanzapine, clozapine; less likely on risperidone[69]) such as:

  • Blurred vision
  • Constipation
  • Dry mouth (although hypersalivation may also occur)
  • Reduced perspiration
  • Tardive dyskinesia appears to be more frequent with high-potency first-generation antipsychotics, such as haloperidol, and tends to appear after chronic and not acute treatment.[70] It is characterized by slow (hence the tardive) repetitive, involuntary and purposeless movements, most often of the face, lips, legs, or torso, which tend to resist treatment and are frequently irreversible. The rate of appearance of TD is about 5% per year of use of antipsychotic drug (whatever the drug used).

Rare/Uncommon (<1% incidence for most antipsychotic drugs) adverse effects of antipsychotics include
  • Blood dyscrasias (e.g., agranulocytosis, leukopaenia, and neutropaenia), which is more common in patients on clozapine.

  • Metabolic syndrome and other metabolic problems such as type II diabetes mellitus — particularly common with clozapine, olanzapine and zotepine. In American studies African Americans appeared to be at a heightened risk for developing type II diabetes mellitus.[71] Evidence suggests that females are more sensitive to the metabolic side effects of first-generation antipsychotic drugs than males.[72] Metabolic adverse effects appear to be mediated by the following mechanisms:

  • Causing weight gain by antagonizing the
histamine H1and serotonin5-HT2Creceptors[73] and perhaps by interacting with other neurochemical pathways in thecentral nervous system.[74]
  • Neuroleptic malignant syndrome a potentially fatal condition characterized by:

  • Autonomic instability, which can manifest with tachycardia, nausea, vomiting, diaphoresis, etc.
  • Hyperthermia — elevated body temperature.
  • Mental status change (confusion, hallucinations, coma, etc.)
  • Muscle rigidity
  • Laboratory abnormalities (e.g., elevated
creatine kinase, reduced iron plasma levels, electrolyte abnormalities, etc.)
  • Pancreatitis[75]

  • QT interval prolongation — more prominent in those treated with amisulpride, pimozide, sertindole, thioridazine and ziprasidone.[7][19]

  • Torsades de pointes

  • Seizures, particularly in people treated with chlorpromazine and clozapine.

  • Thromboembolism

  • Myocardial infarction

  • Stroke

Long-term effects

Some studies have found decreased life expectancy associated with the use of antipsychotics, and argued that more studies are needed.[76][77] Antipsychotics may also increase the risk of early death in individuals with dementia.[78] Antipsychotics typically worsen symptoms in people who suffer from depersonalisation disorder.[79] Antipsychotic polypharmacy (prescribing two or more antipsychotics at the same time for an individual) is a common practice but not evidence-based or recommended, and there are initiatives to curtail it.[66][80] Similarly, the use of excessively high doses (often the result of polypharmacy) continues despite clinical guidelines and evidence indicating that it is usually no more effective but is usually more harmful.[66][81]

Loss of grey matter and other brain structural changes over time are observed in schizophrenia. Meta-analyses of the effects of antipsychotic treatment on the course of grey matter loss and structural changes have reached conflicting conclusions. A 2012 meta-analysis concluded that grey matter loss is greater in patients treated with first generation antipsychotics relative to those treated with atypicals, and hypothesized a protective effect of atypicals as one possible explanation.[82] A second meta-analysis suggested that treatment with antipsychotics was associated with increased grey matter loss.[83]

Subtle, long-lasting forms of akathisia are often overlooked or confused with post-psychotic depression, in particular when they lack the extrapyramidal aspect that psychiatrists have been taught to expect when looking for signs of akathisia.[84]


The British National Formulary recommends a gradual withdrawal when discontinuing antipsychotics to avoid acute withdrawal syndrome or rapid relapse.[85] Symptoms of withdrawal commonly include nausea, vomiting, and loss of appetite.[86] Other symptoms may include restlessness, increased sweating, and trouble sleeping.[86] Less commonly there may be a feeling of the world spinning, numbness, or muscle pains.[86] Symptoms generally resolve after a short period of time.[86]

There is tentative evidence that discontinuation of antipsychotics can result in psychosis.[87] It may also result in reoccurrence of the condition that is being treated.[88] Rarely tardive dyskinesia can occur when the medication is stopped.[86]

Unexpected psychotic episodes have been observed in patients withdrawing from clozapine. This is referred to as supersensitivity psychosis, not to be equated with tardive psychosis.[87]

Tardive dyskinesia may abate during withdrawal from the antipsychotic agent, or it may persist.[89]

Withdrawal effects may also occur when switching a person from one antipsychotic to another, (it is presumed due to variations of potency and receptor activity). Such withdrawal effects can include cholinergic rebound, an activation syndrome, and motor syndromes including dyskinesias. These adverse effects are more likely during rapid changes between antipsychotic agents, so making a gradual change between antipsychotics minimises these withdrawal effects.[90] The British National Formulary recommends a gradual withdrawal when discontinuing antipsychotic treatment to avoid acute withdrawal syndrome or rapid relapse.[91] The process of cross-titration involves gradually increasing the dose of the new medication while gradually decreasing the dose of the old medication.[70]

List of agents







Clinically used antipsychotic medications are listed below by drug group. Trade names appear in parentheses. A 2013 review has stated that the division of antipsychotics into first and second generation is perhaps not accurate.[19]


† indicates drugs that are no longer (or were never) marketed in English-speaking countries.

‡ denotes drugs that are no longer (or were never to begin with) marketed in the United States. Some antipsychotics are not firmly placed in either first-generation or second-generation classes.

# denotes drugs that have been withdrawn worldwide.

First-generation (typical)


  • Benperidol‡

  • Bromperidol†

  • Droperidol‡

  • Haloperidol

  • Moperone (discontinued)†

  • Pipamperone (discontinued)†

  • Timiperone †


  • Fluspirilene ‡

  • Penfluridol ‡

  • Pimozide


  • Acepromazine † — although it is mostly used in veterinary medicine.

  • Chlorpromazine

  • Cyamemazine †

  • Dixyrazine †

  • Fluphenazine

  • Levomepromazine‡

  • Mesoridazine (discontinued)†

  • Perazine

  • Pericyazine‡

  • Perphenazine

  • Pipotiazine ‡

  • Prochlorperazine

  • Promazine (discontinued)

  • Promethazine

  • Prothipendyl †

  • Thioproperazine‡ (only English-speaking country it is available in is Canada)

  • Thioridazine (discontinued)

  • Trifluoperazine

  • Triflupromazine (discontinued)†


  • Chlorprothixene †

  • Clopenthixol

  • Flupentixol ‡

  • Thiothixene

  • Zuclopenthixol ‡


This category is for drugs that have been called both first and second-generation, depending on the literature being used.


  • Sulpiride ‡

  • Sultopride †

  • Veralipride †


  • Carpipramine †

  • Clocapramine †

  • Clorotepine †

  • Clotiapine ‡

  • Loxapine

  • Mosapramine †


  • Molindone #

Second-generation (atypical)


  • Amisulpride ‡ – Selective dopamine antagonist. Higher doses (greater than 400 mg) act upon post-synaptic dopamine receptors resulting in a reduction in the positive symptoms of schizophrenia, such as psychosis. Lower doses, however, act upon dopamine autoreceptors, resulting in increased dopamine transmission, improving the negative symptoms of schizophrenia. Lower doses of amisulpride have also been shown to have antidepressant and anxiolytic effects in non-schizophrenic patients, leading to its use in dysthymia and social phobias.

  • Nemonapride † – Used in Japan.

  • Remoxipride # – Has a risk of causing aplastic anaemia and, hence, has been withdrawn from the market worldwide. It has also been found to possess relatively low (virtually absent) potential to induce hyperprolactinaemia and extrapyramidal symptoms, likely attributable to its comparatively weak binding to (and, hence, rapid dissociation from) the D2 receptor.[92]

  • Sultopride – An atypical antipsychotic of the benzamide chemical class used in Europe, Japan, and Hong Kong for the treatment of schizophrenia. It was launched by Sanofi-Aventis in 1976. Sultopride acts as a selective D2 and D3 receptor antagonist.


  • Iloperidone – Approved by the US FDA in 2009, it is fairly well tolerated, although hypotension, dizziness, and somnolence were very common side effects. Has not received regulatory approval in other countries, however.

  • Lurasidone – Approved by the US FDA for schizophrenia and bipolar depression. Given once daily, it has shown mixed Phase III efficacy results but has a relatively well-tolerated side effect profile. It is also licensed for use as schizophrenia treatment in Canada. Not yet licensed elsewhere, however. Has procognitive effects via its antagonism of the 5-HT7 receptor.

  • Paliperidone – Primary, active metabolite of risperidone that was approved in 2006.

  • Paliperidone palmitate – Long-acting version of paliperidone for once-monthly injection.

  • Perospirone † – Has a higher incidence of extrapyramidal side effects than other atypical antipsychotics.[93]

  • Risperidone – Divided dosing is recommended until initial titration is completed, at which time the drug can be administered once daily. Used off-label to treat Tourette syndrome and anxiety disorder.

  • Ziprasidone – Approved in 2004[94] to treat bipolar disorder. Side-effects include a prolonged QT interval in the heart, which can be dangerous for patients with heart disease or those taking other drugs that prolong the QT interval.


  • Melperone † – Only used in a few European countries. No English-speaking country has licensed it to date.


  • Aripiprazole – Partial agonist at the D2 receptor unlike almost all other clinically-utilized antipsychotics.[[95]](https://portal.issn.org/resource/ISSN/the original)

  • Aripiprazole lauroxil – Long-acting version of aripiprazole for injection.

  • Brexpiprazole – Partial agonist of the D2 receptor. Successor of aripiprazole.

  • Cariprazine – A D3-preferring D2/D3 partial agonist.


  • Asenapine – Used for the treatment of schizophrenia and acute mania associated with bipolar disorder.

  • Clozapine – Requires routine laboratory monitoring of complete blood counts every one to four weeks due to the risk of agranulocytosis. It has unparalleled efficacy in the treatment of treatment-resistant schizophrenia.

  • Olanzapine – Used to treat psychotic disorders including schizophrenia, acute manic episodes, and maintenance of bipolar disorder. Used as an adjunct to antidepressant therapy, either alone or in combination with fluoxetine as Symbyax.

  • Quetiapine – Used primarily to treat bipolar disorder and schizophrenia. Also used and licensed in a few countries (including Australia, the United Kingdom and the United States) as an adjunct to antidepressant therapy in patients with major depressive disorder. It's the only antipsychotic that's demonstrated efficacy as a monotherapy for the treatment of major depressive disorder. It indirectly serves as a norepinephrine reuptake inhibitor by means of its active metabolite, norquetiapine.

  • Zotepine – An atypical antipsychotic indicated for acute and chronic schizophrenia. It is still used in Japan and was once used in Germany but it was discontinued.†


  • Blonanserin – Approved by the PMDA in 2008. Used in Japan and South Korea.

  • Pimavanserin – A selective 5-HT2A receptor antagonist approved for the treatment of Parkinson's disease psychosis in 2016.

  • Sertindole ‡ – Developed by the Danish pharmaceutical company H. Lundbeck. Like the other atypical antipsychotics, it is believed to have antagonist activity at dopamine and serotonin receptors in the brain.

Mechanism of action

Antipsychotic drugs such as haloperidol and chlorpromazine tend to block dopamine D2 receptors in the dopaminergic pathways of the brain. This means that dopamine released in these pathways has less effect. Excess release of dopamine in the mesolimbic pathway has been linked to psychotic experiences. Decreased dopamine release in the prefrontal cortex, and excess dopamine release in other pathways, are associated with psychotic episodes in schizophrenia and bipolar disorder.[96][97] In addition to the antagonistic effects of dopamine, antipsychotics (in particular atypical neuroleptics) also antagonize 5-HT2A receptors. Different alleles of the 5-HT2A receptor have been associated with schizophrenia and other psychoses, including depression.[98][99] Higher concentrations of 5-HT2A receptors in cortical and subcortical areas, in particular in the right caudate nucleus have been historically recorded.[98]

Typical antipsychotics are not particularly selective and also block dopamine receptors in the mesocortical pathway, tuberoinfundibular pathway, and the nigrostriatal pathway. Blocking D2 receptors in these other pathways is thought to produce some unwanted side effects that the typical antipsychotics can produce (see above). They were commonly classified on a spectrum of low potency to high potency, where potency referred to the ability of the drug to bind to dopamine receptors, and not to the effectiveness of the drug. High-potency antipsychotics such as haloperidol, in general, have doses of a few milligrams and cause less sleepiness and calming effects than low-potency antipsychotics such as chlorpromazine and thioridazine, which have dosages of several hundred milligrams. The latter have a greater degree of anticholinergic and antihistaminergic activity, which can counteract dopamine-related side-effects.

Atypical antipsychotic drugs have a similar blocking effect on D2 receptors; however, most also act on serotonin receptors, especially 5-HT2A and 5-HT2C receptors. Both clozapine and quetiapine appear to bind just long enough to elicit antipsychotic effects but not long enough to induce extrapyramidal side effects and prolactin hypersecretion.[100] 5-HT2A antagonism increases dopaminergic activity in the nigrostriatal pathway, leading to a lowered extrapyramidal side effect liability among the atypical antipsychotics.[100][101]

Comparison of medications

Generic nameClassTypeBrand name(s)LaunchDeveloper/Originator(s)Refs
AripiprazolePhenylpiperazine/QuinolinoneAtypicalAbilify2002Otsuka/Bristol-Myers Squibb[102][105]
Aripiprazole lauroxilPhenylpiperazine/QuinolinoneAtypicalAristada2015Alkermes[106]
BlonanserinPyridinylpiperazineAtypicalLonasen2008Sumitomo Dainippon/Mitsubishi Tanabe[102][108]
CariprazinePhenylpiperazineAtypicalVraylar/Reagila2015Gedeon Richter/Actavis[110]
CarpipramineTricyclic/DibenzazepineDisputedDefecton/Prazinil1977Pierre Fabre[102]
FluphenazineTricyclic/PhenothiazineTypicalProlixin1959Bristol-Myers Squibb[102][105]
LurasidoneBenzisothiazoleAtypicalLatuda2010Sumitomo Dainippon/Sunovion[124]
MosapramineTricyclic/DibenzazepineDisputedCremin1991Mitsubishi Pharma[102]
PaliperidoneBenzisoxazoleAtypicalInvega2007Janssen-Cilag/Johnson & Johnson[102][126]
Paliperidone palmitateBenzisoxazoleAtypicalInvega Sustenna/Xeplion2009Janssen-Cilag/Johnson & Johnson[127]
PerospironeBenzisothiazoleAtypicalLullan2001Sumitomo Dainippon/Mitsubishi Tanabe[102][132]
PimavanserinDibenzylpiperidinylureaAtypicalNuplazid2016ACADIA Pharmaceuticals[133]
TriflupromazineTricyclic/PhenothiazineTypicalVesprin1957Bristol-Myers Squibb[102]
Generic name
Discontinuation rate[19](OR with 95% CI in brackets)Anticholinergic effectsSedationEPSEWeight GainMetabolic AEsQTc prolongation (ORs & 95% CIs)PEHypotensionNotes (e.g. notable AEs*)
Amisulpride0.43 (0.32-0.57)
+/-+++ (0.66 [0.39-0.91])+++/++
Torsades de Pointes common on overdose.[141] Has a comparatively low penetrability of the blood-brain barrier.
Amoxapine?+++++/-++/+++/+++/+++/+++/+Amoxapine is also an antidepressant. Very toxic in overdose due to the potential for renal failure and seizures.
Aripiprazole0.61 (0.51-0.72)
+/- (Akathisia mostly)
  • (0.01 [–0.13-0·15])
  • (can reduce prolactin levels)
Only clinically-utilised antipsychotic that does not act by antagonising the D2 receptor and rather partially agonises this receptor.
Asenapine0.69 (0.54-0.86)
+/-++/+ (0.30 [–0.04-0.65])
Oral hypoesthesia. Has a complex pharmacologic profile.
++/++/-Only used in a few East Asian countries.
Chlorpromazine0.65 (0.5-0.84)++++++++++++++++++++First marketed antipsychotic, sort of the prototypical low-potency first-generation (typical) antipsychotic.
Clozapine0.46 (0.32-0.65)++++++
+++Notable AEs: Agranulocytosis, neutropaenia, leukopaenia and myocarditis. Dose-dependent seizure risk.[144] Overall the most effective antipsychotic, on average. Usually reserved for treatment-resistant cases or highly suicidal patients.
Droperidol?+/-+/-++++/-+/-?+++?Mostly used for postoperative nausea and vomiting.
Also used in lower doses for depression.
Fluphenazine0.69 (0.24-1.97)[145]++
High-potency first-generation (typical) antipsychotic.
Haloperidol0.8 (0.71-0.90)
  • (0.11 [0.03-0.19])
Prototypical high-potency first-generation (typical) antipsychotic.
Iloperidone0.69 (0.56-0.84)
++++++ (0.34 [0.22-0.46])++/+
Levomepromazine?++++++++/+++++?++++++Also used as an analgesic, agitation, anxiety and emesis.
Loxapine0.52 (0.28-0.98)[146]
Lurasidone0.77 (0.61-0.96)
  • (–0.10 [–0.21-0.01])
May be particularly helpful in ameloriating the cognitive symptoms of schizophrenia, likely due to its 5-HT7 receptor.[147]
++/+Several smaller low-quality clinical studies have reported its efficacy in the treatment of treatment-resistant schizophrenia. Only approved for use in a few European countries. It is known that off-licence prescribing of melperone is occurring in the United Kingdom.[148] Is a butyrophenone, low-potency atypical antipsychotic that has been tried as a treatment for Parkinson's disease psychosis, although with negative results.
?++++/-Withdrawn from the market. Seems to promote weight loss (which is rather unusual for an antipsychotic seeing how they tend to promote weight gain).[149]
Olanzapine0.46 (0.41-0.52)
  • (0.22 [0.11-0.31])
Paliperidone0.48 (0.39-0.58)
++/+ (dose-dependent)++
  • (0.05 [–0.18-0.26])
+++++Active metabolite of risperidone.
Perazine0.62 (0.4-1.10)[150]????????Limited data available on adverse effects.
?+++++Also used to treat severe anxiety. Not licensed for use in the US.
Usually grouped with the atypical antipsychotics despite its relatively high propensity for causing extrapyramidal side effects.[152]
Perphenazine0.30 (0.04, 2.33)[153]
Has additional antiemetic effects.
Pimozide1.01 (0.30 to 3.39)[154]
High potency first-generation (typical) antipsychotic.
?+++++Only available in the UK.
+++?Primarily used in medicine as an antiemetic.
Quetiapine0.61 (0.52-0.71)++/+++
  • (0.17 [0.06-0.29])
++Binds to the D2 receptor in a hit and run fashion. That is it rapidly dissociates from said receptor and hence produces antipsychotic effects but does not bind to the receptor long enough to produce extrapyramidal side effects and hyperprolactinaemia.
Removed from the market amidst concerns about an alarmingly high rate of aplastic anaemia.
Risperidone0.53 (0.46-0.60)
++/+ (dose-dependent)++++++/+++ (0.25 [0.15-0.36])+++++?
Sertindole0.78 (0.61-0.98)
++++/++++ (0.90 [0.76-1.02])
+++Not licensed for use in the US.
Sulpiride1.00 (0.25-4.00)[155]
Not licensed for use in the US.
Thioridazine0.67 (0.32-1.40)[156]++++++
+++++++++++++Dose-dependent risk for degenerative retinopathies.[157] Found utility in reducing the resistance of multidrug and even extensively resistant strains of tuberculosis to antibiotics.
Trifluoperazine0.94 (0.59-1.48)[158]+/-
Ziprasidone0.72 (0.59 to 0.86)
++ (0.41 [0.31 to 0.51])++/+
Zotepine0.69 (0.41 to 1.07)
++++++++/+++++/+++++++++Dose-dependent risk of seizures.[159] Not licensed for use in the US.
Not licensed for use in the US.
Note: "Notable" is to mean side-effects that are particularly unique to the antipsychotic drug in question. For example, clozapine is notorious for its ability to cause agranulocytosis. If data on the propensity of a particular drug to cause a particular AE is unavailable an estimation is substituted based on the pharmacologic profile of the drug.
Generic drug nameSchizophrenia[5][19]Mania[160][161]Bipolar depression[162]Bipolar maintenance[163][164]Adjunct in major depression[165]
Amisulpride+++???? (+++ in dysthymia)
++ (prevents manic and mixed but not depressive episodes)+++
Loxapine+++/+++++ (only in the treatment of agitation)???
Olanzapine++++++/++++++ (most effective at preventing manic/mixed relapse)++
Binding affinity
Ki[nM] toward cloned human receptors (unless otherwise specified)[1]
Drug name[73][167]SERT5-HT1A5-HT2A5-HT2C5-HT65-HT7α1Aα2Aα2CNETD1D2D3D45-HT2A/D2H1M1M3
Blonanserin[169]ND8040.81226.441.918326.7 (RB)530 (RC)NDND1,0700.1420.4941505.72765100ND
N-DEBN[142]NDND1.284.505.03206 (RC)NDNDNDND1,0201.380.23ND0.93NDNDND
Norclozapine316.613.910.911.9 (RC)11.660.1104.8137.6117.7493.914.394.515363.940.1153.467.695.7
cis-FlupenthixolND8,02887.5 (HFC)102.2 (RC)NDNDNDNDNDND3.50.351.7566.32500.86NDND
Amoxapine58ND0.52.0 (RC)5040.2150NDND16ND20.821.021.00.0240251,0001,000
MelperoneND2,200 (HB)2302,100 (HB)1,254 (RC)578 (HB)180 (HB)150 (HB)NDNDND1948.955551.186580
1.450.251.833.34692.2800 (HB)1,955
ProchlorperazineND5,900 (HC)15 (HC)122148 (RC)196 (RC)23.8 (HB)1,694.91 (HB)NDNDND0.652.905.4023.118.86 (HB)555.55 (HB)ND
Norquetiapine[171]ND4548107ND76144237ND1299.8 (RC)196NDND0.2453.538.3 (RC)ND
10,000 (RC)
10,000 (RC)
5,000 (RC)4,000 (RC)
10,000 (RB)
4,893 (RB)NDND
10,000 (RB)
10,000 (RB)
10,000 (RB)
Acronyms used:
Drug[172][173][174][175]Bioavailabilityt1/2 parent drug
(active metabolite)
Protein bindingtmaxCmaxVdExcretionRoutesMetabolism enzymes[73]Active metabolites
Amisulpride48%12 h16%3-4 h54 ± 4 ng/mL5.8 L/kgFaeces (20%), urine (50%, when given IV)Oral?None
Aripiprazole87% (Oral), 100% (IM)75 h (94 h)99%3-5 h?4.9 L/kgFaeces (55%), urine (25%)Oral, IM (including depot)CYP2D6, CYP3A4Dehydroaripiprazole
Asenapine35% (sublingual)24 h95%0.5-1.5 h4 ng/mL20-25 L/kgUrine (50%), faeces (40%)SublingualCYP1A2, UGT1A4, CYP2D6None
Blonanserin[142][143][176]55%10.7-16.2 h (single dosing), 67.9 h (repeated dosing)≥ 99.7%1.5-2 h0.14-0.76 ng/mL (0.57 ng/mL for repeated dosing)8560-9500 LUrine (59%), faeces (30%)OralCYP3A4N-desethylblonanserin
Chlorpromazine20%30 h92-97%??20 L/kgUrineOral, IM, IVCYP2D6Several active metabolites
Clozapine50-60%12 h97%1.5-2.5 h102-771 ng/mL4.67 L/kgUrine (50%), faeces (30%)OralCYP1A2, CYP2D6, CYP3A4Norclozapine
Droperidol?2 h (8-12 h)Extensive60 min (IM)?2 L/kg (adults), 0.58 L/kg (children)Urine (75%), faeces (22%)IM, IV?None
Flupentixol40-55% (Oral)35 h?7 days (depot)?12-14 L/kgUrineOral, IM (including depot)?None
Fluphenazine2.7% (Oral)14-16 h, 14 days (depot)?2 h (Oral), 8-10 h (depot)??Urine, faecesOral, IM (including depot)?None
Haloperidol60-70% (Oral)10-20 h (short-acting IM), 3 weeks (depot)92%2-6 h (Oral), 10-20 min (short-acting IM), 6–7 days (depot)?8-18 L/kgUrine (30%), faeces (15%)Oral, IM, IVCYP3A4None
Iloperidone96%?95%2-4 h?1340-2800 LUrine (45-58%), faeces (20-22%)OralCYP3A4, CYP2D6None notable.
Levomepromazine?30 h?2-3 h??Urine, faecesIM, IV?Methotrimeprazine sulfoxide
LoxapineHigh6-8 h (Inhaled), 4-12 h (Oral)96.6%2 min (inhaled), 2 h (oral), 5 h (IM)257 ng/mL (inhaled), 6-13 ng/mL (Oral)?Urine (56-70%), faeces [Only oral data available]Oral, IM, InhalationCYP1A2, CYP3A4, CYP2D6Amoxapine (a tricyclic antidepressant), 7-OH loxapine, 8-OH loxapine
Lurasidone9-19%18 h99%1-3 h?6173 LUrine (9%), faeces (80%)OralCYP3A42 active
Melperone[177]54% (Oral via syrup), 65% (Oral via tablets), 87% (IM)2.1-6.4 h (Oral),6.6 ± 3.7 h(IM)50%1.6-2.4 h (Oral, tablets), 1 h (Oral, syrup)1132 ± 814 ng/mL(25 mg, orally), 2228-3416 ng/mL (50 mg, orally),89539 ± 37001 ng/mL(100 mg, orally)9.9 ± 3.7 L/kg(10 mg),7 ± 1.61 L/kg(20 mg)Urine (70% as metabolites, 5.5-10.4% as parent drug)Oral, IM?None
Olanzapine87% (Oral)30 h93%6 h (Oral), 15-45 min (short-acting IM), 7 days (depot)4-20.4 mg/mL[178]1000 LUrine (57%), faeces (30%)Oral, IM (including depot)CYP1A2None
Paliperidone28% (Oral)23 h (Oral), 25–49 days (IM)74%24 h (Oral), 13 days (IM)8.85-11.7 ng/mL[179]390-487 LUrine (80%), faeces (11%)Oral, IM (depot)CYP3A4, CYP2D6None
Periciazine?12 h?2 h150 ng/mL?UrineOral??
Perospirone[93]?1.9-2.5 h92%1.5 h5.7 ng/mL?Urine (0.4% as unchanged drug)Oral?None
Perphenazine?9-12 h (10-19 h)?1-3 h; 2-4 h (metabolite)0.984 ng/mL; 0.509 ng/mL?Urine, faecesOralCYP2D67-OH perphenazine
Pimozide40-50%55 h?6-8 h4-19 ng/mL (dose-dependent)?UrineOralCYP3A4, CYP2D6None
Prochlorperazine12.5%6.8-9 hHigh??12.9-17.7 L/hUrine, bileOral, IM, IV?N-desmethylprochlorperazine
Quetiapine100%6 h (IR), 7 h (XR); active metabolite: 12 h83%1.5 h (IR), 6 h (XR)@ 250 mg q8hr 778 ng/mL (male), 879 ng/mL (female)[180]6-14 L/kgUrine (73%), faeces (20%)OralCYP3A4Norquetiapine (a norepinephrine reuptake inhibitor and 5-HT1A receptor partial agonist)
Risperidone70%3-17 h (24 h)90% (active metabolite: 77%)3-17 h?1-2 L/kgUrine (70%), faeces (14%)Oral, IM (including depot)CYP2D6Paliperidone
Sertindole?3 days99.5%10 h?20 L/kgUrine (4%), faeces (46-56%)OralCYP2D6None
Sulpiride[181]27 ± 9%8 h40%3-6 h?2.72 ± 0.66 L/kgUrine, faecesOral?None
Thioridazine?24 h95%????OralCYP2D6None
Tiotixene?24 h90%????OralCYP1A2None
Trifluoperazine?24 h?????Oral?None
Ziprasidone60% (Oral), 100% (IM)7 h (Oral), 2-5 h (IM)99%6-8 h (Oral), ≤ 60 min (IM)?1.5 L/kgFaeces (66%), urine (20%)Oral, IMCYP3A4, CYP1A2None
Zotepine[182][183]7-13%13.7-15.9 h (12 h)97%1-4 h31-24010 L/kgUrine (17%)OralCYP1A2, CYP3A4Norzotepine (a norepinephrine reuptake inhibitor)
Zuclopenthixol49%20 h98%2-12 h (mean: 4 h)?20 L/kgFaeces, urine (10%)Oral, IM (including depot)CYP2D6None


Advertisement for Thorazine (chlorpromazine) from the 1950s, reflecting the perceptions of psychosis, including the now-discredited perception of a tendency towards violence, from the time when antipsychotics were discovered

Advertisement for Thorazine (chlorpromazine) from the 1950s, reflecting the perceptions of psychosis, including the now-discredited perception of a tendency towards violence, from the time when antipsychotics were discovered[184]

The original antipsychotic drugs were happened upon largely by chance and then tested for their effectiveness. The first, chlorpromazine, was developed as a surgical anesthetic. It was first used on psychiatric patients because of its powerful calming effect; at the time it was regarded as a non-permanent "pharmacological lobotomy".[185] Lobotomy at the time was used to treat many behavioral disorders, including psychosis, although its effect was to markedly reduce behavior and mental functioning of all types. However, chlorpromazine proved to reduce the effects of psychosis in a more effective and specific manner than lobotomy, even though it was known to be capable of causing severe sedation. The underlying neurochemistry involved has since been studied in detail, and subsequent antipsychotic drugs have been discovered by an approach that incorporates this sort of information.

The discovery of chlorpromazine's psychoactive effects in 1952 led to further research that resulted in the development of antidepressants, anxiolytics, and the majority of other drugs now used in the management of psychiatric conditions. In 1952, Henri Laborit described chlorpromazine only as inducing indifference towards what was happening around them in nonpsychotic, nonmanic patients, and Jean Delay and Pierre Deniker described it as controlling manic or psychotic agitation. The former claimed to have discovered a treatment for agitation in anyone, and the latter team claimed to have discovered a treatment for psychotic illness.[186]

Until the 1970s there was considerable debate within psychiatry on the most appropriate term to use to describe the new drugs.[187] In the late 1950s the most widely used term was "neuroleptic", followed by "major tranquilizer" and then "ataraxic".[187] The first recorded use of the term tranquilizer dates from the early nineteenth century.[188] In 1953 Frederik F. Yonkman, a chemist at the Swiss-based Cibapharmaceutical company, first used the term tranquilizer to differentiate reserpine from the older sedatives.[189] The word neuroleptic was coined in 1955 by Delay and Deniker after their discovery (1952) of the antipsychotic effects of chlorpromazine.[187] It is derived from the Greek: "νεῦρον" (neuron, originally meaning "sinew" but today referring to the nerves) and "λαμβάνω" (lambanō, meaning "take hold of"). Thus, the word means taking hold of one's nerves. It was often taken to refer also to common side effects such as reduced activity in general, as well as lethargy and impaired motor control. Although these effects are unpleasant and in some cases harmful, they were at one time, along with akathisia, considered a reliable sign that the drug was working.[185] The term "ataraxy" was coined by the neurologist Howard Fabing and the classicist Alister Cameron to describe the observed effect of psychic indifference and detachment in patients treated with chlorpromazine.[190] This term derived from the Greek adjective "ἀτάρακτος" (ataraktos), which means "not disturbed, not excited, without confusion, steady, calm".[187] In the use of the terms "tranquilizer" and "ataractic", medical practitioners distinguished between the "major tranquilizers" or "major ataractics", which referred to drugs used to treat psychoses, and the "minor tranquilizers" or "minor ataractics", which referred to drugs used to treat neuroses.[187] While popular during the 1950s, these terms are infrequently used today. They are being abandoned in favor of "antipsychotic", which refers to the drug's desired effects.[187] Today, "minor tranquilizer" can refer to anxiolytic and/or hypnotic drugs such as the benzodiazepines and nonbenzodiazepines, which have some antipsychotic properties and are recommended for concurrent use with antipsychotics, and are useful for insomnia or drug-induced psychosis.[191] They are powerful (and potentially addictive) sedatives.

Antipsychotics are broadly divided into two groups, the typical or first-generation antipsychotics and the atypical or second-generation antipsychotics. The typical antipsychotics are classified according to their chemical structure while the atypical antipsychotics are classified according to their pharmacological properties. These include serotonin-dopamine antagonists (see dopamine antagonist and serotonin antagonist), multi-acting receptor-targeted antipsychotics (MARTA, those targeting several systems), and dopamine partial agonists, which are often categorized as atypicals.[192]

Society and culture


The term major tranquilizer was used for older antipsychotic drugs. The term neuroleptic is often used as a synonym for antipsychotic, even though - strictly speaking - the two terms are not interchangeable. Antipsychotic drugs are a subgroup of neuroleptic drugs, because the latter have a wider range of effects.[193][194]

Antipsychotics are a type of psychoactive or psychotropic medication.[195] [196]


Antipsychotics were once among the biggest selling and most profitable of all drugs, generating $22 billion in global sales in 2008.[197] By 2003 in the US, an estimated 3.21 million patients received antipsychotics, worth an estimated $2.82 billion. Over 2/3 of prescriptions were for the newer, more expensive atypicals, each costing on average $164 per year, compared to $40 for the older types.[198] By 2008, sales in the US reached $14.6 billion, the biggest selling drugs in the US by therapeutic class.[199]


Antipsychotics are sometimes administered as part of compulsory psychiatric treatment via inpatient (hospital) commitment or outpatient commitment. They may be administered orally or, in some cases, through long-acting (depot) injections administered in the dorsgluteal, ventrogluteal or deltoid muscle.


Joanna Moncrieff has argued that antipsychotic drug treatment is often undertaken as a means of control rather than to treat specific symptoms experienced by the patient.[200]

Use of this class of drugs has a history of criticism in residential care. As the drugs used can make patients calmer and more compliant, critics claim that the drugs can be overused. Outside doctors can feel under pressure from care home staff.[201] In an official review commissioned by UK government ministers it was reported that the needless use of antipsychotic medication in dementia care was widespread and was linked to 1800 deaths per year.[202][203] In the US, the government has initiated legal action against the pharmaceutical company Johnson & Johnson for allegedly paying kickbacks to Omnicare to promote its antipsychotic risperidone (Risperdal) in nursing homes.[204]

There has also been controversy about the role of pharmaceutical companies in marketing and promoting antipsychotics, including allegations of downplaying or covering up adverse effects, expanding the number of conditions or illegally promoting off-label usage; influencing drug trials (or their publication) to try to show that the expensive and profitable newer atypicals were superior to the older cheaper typicals that were out of patent. Following charges of illegal marketing, settlements by two large pharmaceutical companies in the US set records for the largest criminal fines ever imposed on corporations.[205] One case involved Eli Lilly and Company's antipsychotic Zyprexa, and the other involved Bextra. In the Bextra case, the government also charged Pfizer with illegally marketing another antipsychotic, Geodon.[205] In addition, Astrazeneca faces numerous personal-injury lawsuits from former users of Seroquel (quetiapine), amidst federal investigations of its marketing practices.[206] By expanding the conditions for which they were indicated, Astrazeneca's Seroquel and Eli Lilly's Zyprexa had become the biggest selling antipsychotics in 2008 with global sales of $5.5 billion and $5.4 billion respectively.[197]

Harvard medical professor Joseph Biederman conducted research on bipolar disorder in children that led to an increase in such diagnoses. A 2008 Senate investigation found that Biederman also received $1.6 million in speaking and consulting fees between 2000 and 2007 — some of them undisclosed to Harvard — from companies including makers of antipsychotic drugs prescribed for children with bipolar disorder. Johnson & Johnson gave more than $700,000 to a research center that was headed by Biederman from 2002 to 2005, where research was conducted, in part, on Risperdal, the company's antipsychotic drug. Biederman has responded saying that the money did not influence him and that he did not promote a specific diagnosis or treatment.[205]

Pharmaceutical companies have also been accused of attempting to set the mental health agenda through activities such as funding consumer advocacy groups.[207]

Special populations

It is recommended that persons with dementia who exhibit behavioral and psychological symptoms should not be given antipsychotics before trying other treatments.[208] When taking antipsychotics this population has increased risk of cerebrovascular effects, parkinsonism or extrapyramidal symptoms, sedation, confusion and other cognitive adverse effects, weight gain, and increased mortality.[208] Physicians and caretakers of persons with dementia should try to address symptoms including agitation, aggression, apathy, anxiety, depression, irritability, and psychosis with alternative treatments whenever antipsychotic use can be replaced or reduced.[208] Elderly persons often have their dementia treated first with antipsychotics and this is not the best management strategy.[209]

See also

  • List of investigational antipsychotics

  • Antipsychotic switching


Citation Linkopenlibrary.orgBolded drug names indicates drugs that are metabolites of clinically-marketed antipsychotics
Sep 19, 2019, 3:53 AM
Citation Linkweb.archive.orgFinkel RF, Clark MA, Cubeddu LX (2009). Pharmacology. Lippincott Williams & Wilkins. p. 151. ISBN 9780781771559. Archived from the original on 1 April 2017.
Sep 19, 2019, 3:53 AM
Citation Linkportal.issn.orgHippius, H. (1 March 1989). "The history of clozapine". Psychopharmacology. 99 (1): S3–S5. doi:10.1007/BF00442551. ISSN 0033-3158. PMID 2682730.
Sep 19, 2019, 3:53 AM
Citation Link//www.ncbi.nlm.nih.gov/pubmed/12066446King C, Voruganti LN (May 2002). "What's in a name? The evolution of the nomenclature of antipsychotic drugs". Journal of Psychiatry & Neuroscience. 27 (3): 168–75. PMC 161646. PMID 12066446.
Sep 19, 2019, 3:53 AM
Citation Link//www.ncbi.nlm.nih.gov/pubmed/19058842Leucht S, Corves C, Arbter D, Engel RR, Li C, Davis JM (January 2009). "Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis". Lancet. 373 (9657): 31–41. doi:10.1016/S0140-6736(08)61764-X. PMID 19058842.
Sep 19, 2019, 3:53 AM
Citation Link//www.ncbi.nlm.nih.gov/pubmed/23089129Goikolea JM, Colom F, Torres I, Capapey J, Valentí M, Undurraga J, Grande I, Sanchez-Moreno J, Vieta E (January 2013). "Lower rate of depressive switch following antimanic treatment with second-generation antipsychotics versus haloperidol". Journal of Affective Disorders. 144 (3): 191–8. doi:10.1016/j.jad.2012.07.038. PMID 23089129.
Sep 19, 2019, 3:53 AM
Citation Linkopenlibrary.orgTaylor D, Paton C, Kapur S, Taylor D (2012). The Maudsley prescribing guidelines in psychiatry (11th ed.). Chichester, West Sussex, UK: Wiley-Blackwell. ISBN 978-0-470-97948-8.
Sep 19, 2019, 3:53 AM
Citation Linkweb.archive.org"American Psychiatric Association Five Things Physicians and Patients Should Question". Choosing Wisely. Archived from the original on 3 December 2013. Retrieved 23 September 2013.
Sep 19, 2019, 3:53 AM
Citation Linkweb.archive.orgAntipsychotic medications for psychotic disorders Archived 20 October 2017 at the Wayback Machine World Health Organization 2012 Accessed October 12th, 2017
Sep 19, 2019, 3:53 AM
Citation Linkweb.archive.org"Psychosis and schizophrenia in adults (CG178)". Archived from the original on 4 March 2014.
Sep 19, 2019, 3:53 AM
Citation Linkpsychiatryonline.org"PsychiatryOnline | Guidelines".
Sep 19, 2019, 3:53 AM
Citation Link//www.ncbi.nlm.nih.gov/pubmed/21292923Barnes TR (May 2011). "Evidence-based guidelines for the pharmacological treatment of schizophrenia: recommendations from the British Association for Psychopharmacology". Journal of Psychopharmacology. 25 (5): 567–620. doi:10.1177/0269881110391123. PMID 21292923.
Sep 19, 2019, 3:53 AM
Citation Link//www.ncbi.nlm.nih.gov/pubmed/22584864Miyamoto S, Miyake N, Jarskog LF, Fleischhacker WW, Lieberman JA (December 2012). "Pharmacological treatment of schizophrenia: a critical review of the pharmacology and clinical effects of current and future therapeutic agents". Molecular Psychiatry. 17 (12): 1206–27. doi:10.1038/mp.2012.47. PMID 22584864.
Sep 19, 2019, 3:53 AM
Citation Link//www.ncbi.nlm.nih.gov/pubmed/22893011Hartling L, Abou-Setta AM, Dursun S, Mousavi SS, Pasichnyk D, Newton AS (October 2012). "Antipsychotics in adults with schizophrenia: comparative effectiveness of first-generation versus second-generation medications: a systematic review and meta-analysis". Annals of Internal Medicine. 157 (7): 498–511. doi:10.7326/0003-4819-157-7-201210020-00525. PMID 22893011.
Sep 19, 2019, 3:53 AM
Citation Link//www.ncbi.nlm.nih.gov/pubmed/25372935Furukawa TA, Levine SZ, Tanaka S, Goldberg Y, Samara M, Davis JM, Cipriani A, Leucht S (January 2015). "Initial severity of schizophrenia and efficacy of antipsychotics: participant-level meta-analysis of 6 placebo-controlled studies". JAMA Psychiatry. 72 (1): 14–21. doi:10.1001/jamapsychiatry.2014.2127. PMID 25372935.
Sep 19, 2019, 3:53 AM
Citation Link//www.ncbi.nlm.nih.gov/pubmed/10416727Keefe RS, Silva SG, Perkins DO, Lieberman JA (1 January 1999). "The effects of atypical antipsychotic drugs on neurocognitive impairment in schizophrenia: a review and meta-analysis". Schizophrenia Bulletin. 25 (2): 201–22. doi:10.1093/oxfordjournals.schbul.a033374. PMID 10416727.
Sep 19, 2019, 3:53 AM
Citation Linkweb.archive.org"NICE Treatment Guidance 2014". Archived from the original on 13 August 2014. Retrieved 7 August 2014.
Sep 19, 2019, 3:53 AM
Citation Link//www.ncbi.nlm.nih.gov/pubmed/18180760Leucht S, Arbter D, Engel RR, Kissling W, Davis JM (April 2009). "How effective are second-generation antipsychotic drugs? A meta-analysis of placebo-controlled trials". Molecular Psychiatry. 14 (4): 429–47. doi:10.1038/sj.mp.4002136. PMID 18180760.
Sep 19, 2019, 3:53 AM
Citation Link//www.ncbi.nlm.nih.gov/pubmed/23810019Leucht S, Cipriani A, Spineli L, Mavridis D, Orey D, Richter F, Samara M, Barbui C, Engel RR, Geddes JR, Kissling W, Stapf MP, Lässig B, Salanti G, Davis JM (September 2013). "Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis". Lancet. 382 (9896): 951–62. doi:10.1016/S0140-6736(13)60733-3. PMID 23810019.
Sep 19, 2019, 3:53 AM
Citation Link//www.ncbi.nlm.nih.gov/pubmed/18616969Beitinger R, Lin J, Kissling W, Leucht S (October 2008). "Comparative remission rates of schizophrenic patients using various remission criteria". Progress in Neuro-Psychopharmacology & Biological Psychiatry. 32 (7): 1643–51. doi:10.1016/j.pnpbp.2008.06.008. PMID 18616969.
Sep 19, 2019, 3:53 AM